Although some immune checkpoint blockade (ICB) therapies, particularly anti-PD-L1/PD-1, have shown clinical efficacy for patients with advanced stages of cancer, the objective response rate and survival benefits remain limitation (26, 27). Here, PDCD1 is linked to cancer.